title: Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
abstract: BACKGROUND
  Several small studies indicated that the genotype of KIT or platelet-derived growth factor receptor-α (PDGFRA) contributes in part to the level of clinical effectiveness of sunitinib in gastrointestinal stromal tumor (GIST) patients. This study aimed to correlate KIT and PDGFRA mutational status with clinical outcome metrics (progression-free survival [PFS], overall survival [OS], objective response rate [ORR]) in a larger international patient population.
  
  
  METHODS
  This is a non-interventional, retrospective analysis in patients with imatinib-resistant or intolerant GIST who were treated in a worldwide, open-label treatment-use study (Study 1036; NCT00094029) in which sunitinib was administered at a starting dose of 50 mg/day on a 4-week-on, 2-week-off schedule. Molecular status was obtained in local laboratories with tumor samples obtained either pre-imatinib, post-imatinib/pre-sunitinib, or post-sunitinib treatment, and all available data were used in the analyses regardless of collection time. The primary analysis compared PFS in patients with primary KIT exon 11 versus exon 9 mutations (using a 2-sided log-rank test) and secondary analyses compared OS (using the same test) and ORR (using a 2-sided Pearson χ(2) test) in the same molecular subgroups.
  
  
  RESULTS
  Of the 1124 sunitinib-treated patients in the treatment-use study, 230 (20%) were included in this analysis, and baseline characteristics were similar between the two study populations. Median PFS was 7.1 months. A significantly better PFS was observed in patients with a primary mutation in KIT exon 9 (n = 42) compared to those with a primary mutation in exon 11 (n = 143; hazard ratio = 0.59; 95 % confidence interval, 0.39-0.89; P = 0.011), with median PFS times of 12.3 and 7.0 months, respectively. Similarly, longer OS and higher ORR were observed in patients with a primary KIT mutation in exon 9 versus exon 11. The data available were limited to investigate the effects of additional KIT or PDGFRA mutations on the efficacy of sunitinib treatment.
  
  
  CONCLUSIONS
  This large retrospective analysis confirms the prognostic significance of KIT mutation status in patients with GIST. This analysis also confirms the effectiveness of sunitinib as a post-imatinib therapy, regardless of mutational status.
  
  
  BACKGROUND
  NCT01459757.
authors.affiliation: Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany. peter.reichardt@helios-kliniken.de.
authors.forename: Peter
authors.initials: P
authors.lastname: Reichardt
authors.affiliation: Ludwig Center at Harvard and Dana-Farber Cancer Institute, Boston, MA, USA. george_demetri@dfci.harvard.edu.
authors.forename: George D
authors.initials: GD
authors.lastname: Demetri
authors.affiliation: Leiden University Medical Center, Leiden, The Netherlands. a.j.gelderblom@lumc.nl.
authors.forename: Hans
authors.initials: H
authors.lastname: Gelderblom
authors.affiliation: Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. rutkowskip@coi.waw.pl.
authors.forename: Piotr
authors.initials: P
authors.lastname: Rutkowski
authors.affiliation: Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. moisa@snu.ac.kr.
authors.forename: Seock-Ah
authors.initials: SA
authors.lastname: Im
authors.affiliation: Tata Memorial Centre, Mumbai, India. sudeepgupta04@yahoo.com.
authors.forename: Sudeep
authors.initials: S
authors.lastname: Gupta
authors.affiliation: Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. ykkang@amc.seoul.kr.
authors.forename: Yoon-Koo
authors.initials: YK
authors.lastname: Kang
authors.affiliation: University Hospitals Leuven, Leuven Cancer Institute, and Laboratory of Experimental Oncology, KU Leuven, Leuven, Belgium. patrick.schoffski@uz.kuleuven.ac.be.
authors.forename: Patrick
authors.initials: P
authors.lastname: Schöffski
authors.affiliation: Hämatoonkologische Schwerpunktpraxis, Düsseldorf, Germany. jochen.schuette@uni-duisburg-essen.de.
authors.forename: Jochen
authors.initials: J
authors.lastname: Schuette
authors.affiliation: Centre Hospitalier de l'Université de Montreal, Montreal, QC, Canada. denis.soulieres@umontreal.ca.
authors.forename: Denis
authors.initials: D
authors.lastname: Soulières
authors.affiliation: Centre Léon Bérard, Université Claude Bernard, Lyon, France. jean-yves.blay@lyon.unicancer.fr.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.affiliation: Prince of Wales Hospital, Sydney, Australia. d.goldstein@unsw.edu.au.
authors.forename: David
authors.initials: D
authors.lastname: Goldstein
authors.affiliation: Pfizer Oncology, Groton, CT, USA. kolette.d.fly@pfizer.com.
authors.forename: Kolette
authors.initials: K
authors.lastname: Fly
authors.affiliation: Pfizer Oncology, La Jolla, CA, USA. xin.huang@pfizer.com.
authors.forename: Xin
authors.initials: X
authors.lastname: Huang
authors.affiliation: Pfizer Oncology, Milan, Italy. massimo.corsaro@pfizer.com.
authors.forename: Massimo
authors.initials: M
authors.lastname: Corsaro
authors.affiliation: Pfizer Oncology, Milan, Italy. mariajose.lechuga@pfizer.com.
authors.forename: Maria Jose
authors.initials: MJ
authors.lastname: Lechuga
authors.affiliation: Pfizer Oncology, La Jolla, CA, USA. jean-francois.martini@pfizer.com.
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Martini
authors.affiliation: VA Portland Health Care System and Oregon Health & Science University, Portland, OR, USA. heinrich@ohsu.edu.
authors.forename: Michael C
authors.initials: MC
authors.lastname: Heinrich
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005838:Genotype; D006801:Humans; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011758:Pyrroles / Q000008:administration & dosage* / Q000009:adverse effects; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D000077210:Sunitinib
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D019009:Proto-Oncogene Proteins c-kit; D020796:Receptor, Platelet-Derived Growth Factor alpha; D000077210:Sunitinib